What Researchers Did
Researchers randomized 45 patients with advanced esophageal cancer to receive either a 125I particle-integrated esophageal covered stent with hyperbaric oxygen or the stent alone.
What They Found
The treatment group showed a total effective rate of 80.7% (19.2% complete remission, 61.5% partial remission), significantly higher than the control group's 63.1% (10.5% complete remission, 52.6% partial remission) (p < 0.05). This combination therapy demonstrated good short- and long-term efficacy.
What This Means for Canadian Patients
This study suggests a potential new treatment approach for advanced esophageal cancer. If validated, this combination therapy could offer improved remission rates for Canadian patients facing this challenging diagnosis.
Canadian Relevance
This study was not conducted in Canada and does not have a direct Canadian connection.
Study Limitations
The study's relatively small sample size of 45 patients may limit the generalizability of its findings.